Health Care & Life Sciences » Biotechnology | Akari Therapeutics PLC

Akari Therapeutics PLC ADR | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,657.00
6,305.60
68,919.80
44,586.30
28,106.70
5,446.10
Total Accounts Receivable
6.00
-
10.40
-
-
-
Other Current Assets
169.00
72.40
728.10
1,529.00
706.40
1,423.20
Total Current Assets
7,832.00
6,378.00
69,658.30
46,115.30
28,813.10
6,869.30
Net Property, Plant & Equipment
-
48.60
40.50
59.00
55.90
20.40
Total Investments and Advances
-
-
142.10
143.70
142.20
521.80
Intangible Assets
-
-
52.50
39.80
39.10
33
Total Assets
7,832.00
6,426.60
69,893.30
46,357.70
29,050.30
8,029.60
Accounts Payable
652.00
994.70
4,320.60
-
-
Other Current Liabilities
579.00
353.10
16,804.30
11,838.40
11,848.40
Total Current Liabilities
1,231.00
1,347.80
21,124.90
11,838.40
11,848.40
Other Liabilities
787.00
265.80
49.10
57.00
48.00
Total Liabilities
2,018.00
1,613.60
21,174.00
11,895.30
11,896.40
Common Equity (Total)
5,814.00
4,813.00
48,719.40
34,462.40
17,154.00
Total Shareholders' Equity
5,814.00
4,813.00
48,719.40
34,462.40
17,154.00
Total Equity
5,814.00
4,813.00
48,719.40
34,462.40
17,154.00
Liabilities & Shareholders' Equity
7,832.00
6,426.60
69,893.30
46,357.70
29,050.30

About Akari Therapeutics

View Profile
Address
75/76 Wimpole Street
London London & South East W1G 9RT
United Kingdom
Employees -
Website http://akaritx.com
Updated 07/08/2019
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Coversin, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.